Sustained Release Excipients Market

Sustained Release Excipients Market Outlook

The global sustained release excipients market was valued at USD 1.29 billion in 2022 and is expected to grow at an 8.22% CAGR from 2022 to 2032. The global market for sustained-release excipients is expected to reach USD 2.84 billion by 2032.

The increasing numbers of patent expirations, as well as the growing demand for geriatric and pediatric population dosage forms, are driving the sustained release excipients market growth. As patients' expectations for greater convenience rise, so does the demand for controlled-release formulations.

The main components of controlled-release formulations are excipients. The sustained release excipients market is being propelled forward by growing awareness of the additional benefits of controlled-release formulations.

Report Attributes	Details
Sustained Release Excipients Market Size (2022)	USD 1.29 billion
Projected Sustained Release Excipients Market Value (2032)	8.22%
Global Sustained Release Excipients Market Share	USD 2.84 billion
Europe Sustained Release Excipients Market Share	36.45%
Targeted Delivery Sustained Release Excipients Market Share	22.6%
Oral Sustained Release Excipients Market Share	40.25%
Polymers Sustained Release Excipients Market Share	43.60%
Key Companies Profiled	Teva Pharmaceutical Industries Ltd. Mylan N.V. Valeant Pharmaceuticals International, Inc. Pfizer, Inc. Sun Pharmaceutical Industries Ltd. Novartis AG AstraZeneca GlaxoSmithKline plc Allergan plc Janssen Pharmaceuticals, Inc. Mayne Pharma Group Ltd. BASF International Flavors & Fragrances, Inc. Ashland Global Evonik Industries Croda International Plc Gattefossé Merck KGaA

Prominent Sustained Release Excipients Market Growth Factors

Conventional formulations are frequently required to be supplied in numerous dosage regimens in long-term therapy for the treatment of chronic illnesses, which has several negative effects. As a result, sustained-release solid unit dosage forms, such as tablets, are required to mitigate the disadvantages of multiple dosing. These elements have had a positive impact on the sustained release excipients market.

Rapidly fueling the market for sustained release excipients includes enabling technology, trends in patient preferences, and increasing physicians' comfort with the ability of persistent drug release to deliver proper blood levels.

Several ongoing efforts have been made to improve oral drug therapeutic efficiency, bioavailability, and patient compliance. To meet the increasing demand for sustained release excipients, several sustained-release oral drug delivery technologies have been developed.

By reducing dosing frequency, these technologies with sustained-release approaches may enhance and improve patient compliance and therapeutic efficacy.

Manufacturers Rely on Agreements to Hack Inorganic Growth

A growing number of collaboration and licencing agreements have been signed for the development of controlled release drug forms in therapeutic areas. As a result, paediatric patients are treated by modifying adult dosage forms. As a result, while pharmaceutical companies manufacture a large portion of their products for adults, paediatric dosage forms are limited.

Sustained release drug delivery forms can also help treat a variety of diseases that affect the elderly. Sustained release dosage forms are simple to use and comfortable for geriatric patients. The use of these drug delivery systems also allows for easy monitoring of drug adherence.

Segmentation Insights

The sustained release excipients market has been further divided into gelatine, polymers, minerals, sugars, alcohol, and chitosan-based on products. More than 43.60% of total revenue came from the polymers product segment, which dominated the global market.

Throughout the forecast period, the market segment is anticipated to continue to grow at the fastest rate while maintaining its leadership position. The use of polymers in the development of sustained-release formulations has significantly increased. For use as an excipient in solid pharmaceutical formulations, polymers have the perfect properties.

Compared to other excipients used in different pharmaceutical preparations, they are stronger and have a longer shelf life. Pharmaceutical polymers of the market for sustained release excipients have evolved over the years, from being used in the preparation of simple gelatin shells to strengthening excipient capsules with ideal formulation features that facilitate controlled/sustained release and help deliver drugs to target sites.

Furthermore, with an increase in the number of formulations containing polyethylene glycol, the excipient has seen tremendous growth in recent years. As a result, the increasing use of polymers is expected to boost segment growth in the market for sustained release excipients.

Insights on the Route of Administration

The sustained release excipients market was dominated by the oral drug delivery segment, which brought in more than 40.25% of the total revenue. It is the simplest and most popular method of drug delivery.

The availability of the maximum active surface area for drug absorption in comparison to other drug delivery methods is one of the major factors behind the high share. Another significant factor that contributes to the widespread use of the oral route of drug administration is the simplicity of producing tablets and capsules.

During the forecast period, the transdermal route of delivery is expected to have the highest CAGR in the market for sustained release excipients. This method of administration reduces the limitations associated with the oral and parenteral routes of administration. As this method avoids gastrointestinal issues caused by drug interactions with food and enzymatic degradation, it is frequently preferred over the oral route of drug delivery.

Insights into Technology

Targeted delivery dominated the sustained release excipients market and accounted for the largest share of the total revenue, or 22.6% when analysed in terms of technology. Targeted delivery involves delivering the medication to a desired site of action and preventing the medication from entering unintended areas of the body, which increases the likelihood of drug toxicity.

During the forecast period, it is anticipated that the transdermal route of technology is anticipated to have the highest CAGR in the market for sustained release excipients. Transdermal sustained release excipients have several advantages over traditional drug delivery methods, including the ability to avoid hepatic first-pass metabolism, significantly reduce adverse drug effects, and improve patient compliance.

The segment is expected to gain a significant revenue share in the near future due to the increased adoption of sustained release excipients.

Country Insights

North America Insights

‘Chronic Diseases Are Becoming More Common in North America Due to Abuse of Drugs (Painkillers)’

Due to their increased drug efficacy and ability to maintain patient safety by requiring fewer doses of medication, sustained release formulations are becoming more and more popular. Reduced doses boost treatment compliance, which could lead to higher unit sales and, consequently, higher revenues from a market perspective.

Additionally, from the perspective of the patient, better therapeutic results are anticipated due to increased drug efficacy and tolerance, which is anticipated to result in lower switching costs and higher physician loyalty.

What is the Growth Outlook for Sustained Release Excipients in the U.S?

As new active pharmaceutical ingredients are created and cutting-edge technologies are adopted, the US sustained release excipients market is anticipated to undergo a significant evolution alongside the growth of the pharmaceutical sector.

During the forecast period, it is possible to anticipate the introduction of novel multifunctional excipients and specialty blends. The demand for sustained release excipients is increasing globally, which has fueled an increase in drug production and, as a result, in the use of excipients in the United States.

Asia Pacific Insights

Asia Pacific, on the other hand, is expected to grow at the fastest rate during the forecast years. This region's growth can be credited to the increasing prevalence of various infectious diseases, quickly growing healthcare infrastructure and rising demand for sustained release excipients.

How Do Growth Prospects Look in the Chinese Sustained Release Excipients Market?

China, in particular, is a growing market in the Asia Pacific region, and the majority of international excipient suppliers are suggesting establishing production facilities in the country in order to capture a large, sustained release excipients market share in terms of revenue generation. These are some of the factors driving the APAC region's expansion.

Europe Insights

Europe dominated the global sustained release excipients market accounting for more than 36.45% of total revenue. The region is anticipated to continue to expand at a steady CAGR, maintaining its leading position throughout the forecast years.

Is Germany to Emerge as an Opportunistic Sustained Release Excipients Market?

The region's expansion is attributed to increased R&D activities and the presence of major pharmaceutical companies in the region. Since of patent expirations and the subsequent entry of generics, the region is expected to grow at a profitable rate over the forecast period.

The increasing collaborations between healthcare organisations in this region to raise awareness about chronic diseases and available treatment options support sustained release excipients market growth.

Comparative View of Adjacent Sustained Release Excipients Market

Sustained Release Excipients Market :

Attributes	Sustained Release Excipients Market
CAGR (2022-2032)	8.22%
Market Value (2027)	USD 1.91 Billion
Growth Factor	The market potential is being positively impacted by a rise in patent expirations, the demand for paediatric and geriatric dosage forms, and the additional advantages offered by sustained release formulations.
Opportunity	Due to these, the use of sustained release formulations has increased, resulting in higher patient compliance and improved therapeutic effect.
Key Trends	The frequency of doses is significantly reduced with sustained release formulations, and patient compliance is increased. These elements are supporting industry growth even more.

Oral Solid Dosage Contract Manufacturing Market :

Attributes	Oral Solid Dosage Contract Manufacturing Market
CAGR (2022-2032)	6.0%
Market Value (2027)	USD 45.25 billion
Growth Factor	The market is expanding as a result of improvements in sustained release dosage forms and drug delivery technology, as well as rising CDMO investments in OSD development and rising consumer demand for novel therapies.
Opportunity	North American OSD producers can now significantly increase bioavailability by utilising new drug delivery platforms thanks to recent developments in drug delivery. The need for oral controlled-release drug delivery technology in the area is anticipated to rise as a result.
Key Trends	It is extremely unlikely that new technologies are anticipated to ever completely replace pharmaceuticals for oral administration. New solid dose formats and improved efficiency are driving the expansion of pharmaceutical manufacturing for solid doses.

Bamboo Furniture Market :

Attributes	Bamboo Furniture Market
CAGR (2022-2032)	5.2%
Market Value (2027)	USD 15.92 Billion
Growth Factor	The growth is primarily attributed to rising infrastructure development investments and the use of environmentally friendly raw materials in furniture manufacturing.
Opportunity	The use of bamboo as a sustainable building material is anticipated to increase as environmental awareness among wood processing businesses grows.
Key Trends	The growth is anticipated to be fueled by awareness of the advantages of using this material for sustainability.

Competitive Landscape

In the global market for sustained release excipients, businesses like BASF Corporation, Ashland Global Holdings Inc., and The Dow Chemical Company account for more than 42.8% of the market's revenue. To increase the penetration of their products in the sustained release excipients market, the companies active in sustained release excipients market are partnering with regional distributors.

The market for sustained release excipients is largely dominated by domestic manufacturers who compete on price. The fragmented nature of the market reduces the business's profitability.

The growing awareness of sustained release excipients, as well as the lack of test specificity and sensitivity for sustained release excipients manufactured by local companies, has increased revenue opportunities for global pharmaceutical excipient manufacturers.

To strengthen their industry presence, key players are implementing various strategies such as partnerships through mergers and acquisitions, geographical expansions, and strategic collaborations.

Recent Development :

Date	Company Name	Strategy	Details
March 2022	Hovione	Expansion	Hovione and Zerion Pharma, which seeks to commercialise the technology for overcoming the difficulties of low drug solubility, expanded their oral drug delivery toolkit in March 2022.
February 2021	DuPont's Nutrition & Biosciences Business	Merger	The merger of DuPont's Nutrition & Biosciences Business and International Flavors & Fragrances was finalised in February 2021. The portfolio's variety of solutions to meet the needs of the industry has increased with the inclusion of Aquacoat products.
April 2019	Colorcon, Inc.	Product Addition	In April 2019, Colorcon, Inc. announced the addition of the Aquacoat line of modified release products to its functional film coatings through the Controlled Release Alliance with DuPont.

Key Segments

• By Product :

  • Gelatin
  • Polymers
  • Minerals
  • Sugars
  • Alcohol
  • Chitosan

• By Route of Administration :

  • Oral
  • Intramuscular
  • Subcutaneous
  • Transdermal
  • Vaginal
  • Ophthalmic
  • Intravenous
  • Other Route of Administrations

• By Technology :

  • Targeted Delivery
  • Micro Encapsulation
  • Wurster Technique
  • Transdermal
  • Implants
  • Coacervation
  • Others

• By Region :

  • North America
  • Latin America
  • Asia Pacific
  • MEA
  • Europe